Updated Follow-up of the Alta Study, a Phase 1/2, Open Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 Gene Therapy in Adult Patients with Severe Hemophilia A

被引：16
|
作者：
Konkle, Barbara A. [1 ,2 ]
Stine, Kimo [3 ]
Visweshwar, Nathan [4 ]
Harrington, Thomas J. [5 ]
Leavitt, Andrew D. [6 ]
Giermasz, Adam [7 ]
Arkin, Steven [8 ]
Di Russo, Gregory [8 ]
Snyder, Ashley [9 ]
Woolfson, Adrian [9 ]
Rouy, Didier [9 ]
机构：
[1] Bloodworks Northwest, Seattle, WA USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Arkansas Childrens Hosp, 800 Marshall St, Little Rock, AR 72202 USA
[4] Univ S Florida, Div Hematol & Med Oncol, Dept Internal Med, Tampa, FL 33620 USA
[5] Univ Miami, Miller Sch Med, Miami, FL 33136 USA
[6] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA USA
[7] Univ Calif Davis, Sacramento, CA 95817 USA
[8] Pfizer Inc, Cambridge, MA USA
[9] Sangamo Therapeut, Brisbane, CA USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-122143
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2060
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Updated Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (SB-525) Gene Therapy in Adults with Severe Hemophilia a
    Leavitt, Andrew D.
    Konkle, Barbara A.
    Stine, Kimo
    Visweshwar, Nathan
    Harrington, Thomas J.
    Giermasz, Adam
    Arkin, Steven
    Fang, Annie
    Plonski, Frank
    Smith, Lynne
    Tseng, Li-Jung
    Di Russo, Gregory
    Cockroft, Bettina M.
    Rupon, Jeremy
    Rouy, Didier
    BLOOD, 2020, 136
  • [2] Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia a
    Visweshwar, Nathan
    Harrington, Thomas J.
    Leavitt, Andrew D.
    Konkle, Barbara A.
    Giermasz, Adam
    Stine, Kimo
    Rupon, Jeremy
    Di Russo, Gregory
    Tseng, Li-Jung
    Resa, Mariade los Angeles
    Ganne, Florence
    Agathon, Delphine
    Plonski, Frank
    Rouy, Didier
    Cockroft, Bettina M.
    Fang, Annie
    Arkin, Steven
    BLOOD, 2021, 138
  • [3] Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia A
    Giermasz, Adam
    Visweshwar, Nathan
    Harrington, Thomas J.
    Leavitt, Andrew D.
    Konkle, Barbara
    Rupon, Jeremy
    Di Russo, Gregory
    Tseng, Li-Jung
    Resa, Maria de los Angeles
    Ganne, Florence
    Agathon, Delphine
    Plonski, Frank
    Rouy, Didier
    Cockroft, Bettina M.
    Fang, Annie
    Arkin, Steven
    BLOOD, 2022, 140 : 7776 - 7777
  • [4] Four-Year Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF-07055480/SB-525) Gene Therapy in Adults with Severe Hemophilia.
    Harrington, Thomas J.
    Giermasz, Adam
    Visweshwar, Nathan
    Leavitt, Andrew D.
    Konkle, Barbara A.
    Rupon, Jeremy
    Dirusso, Gregory
    Tseng, Li-Jung
    Resa, Maria de los Angeles
    Ganne, Florence
    Agathon, Delphine
    Plonski, Frank
    Rouy, Didier
    Cockroft, Bettina M.
    Fang, Annie F.
    Arkin, Steven
    BLOOD, 2023, 142
  • [5] A phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD)
    Wollenberg, Andreas
    Howell, Michael D.
    Guttman-Yassky, Emma
    Silverberg, Jonathan I.
    Birrell, Claire
    Kell, Chris
    Dawson, Michelle
    van der Merwe, Rene
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB20 - AB20
  • [6] Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinson's Disease: Efficacy, Safety, and Tolerability Data up to 24 Months
    Corcoran, G.
    Karunakara, A.
    Dumayas, E.
    Valencia, D.
    De Boever, E.
    Foltynie, T.
    Barker, R. A.
    Palfi, S.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A107 - A107
  • [7] Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection
    Montaner, Julio
    Yeni, Patrick
    Clumeck, Nathan N.
    Faetkenheuer, Gerd
    Gatell, Jose
    Hay, Phillip
    Seminari, Elena
    Peeters, Monika P.
    Schoeller-Gyuere, Monika
    Simonts, Myriam
    Woodfall, Brian
    CLINICAL INFECTIOUS DISEASES, 2008, 47 (07) : 969 - 978
  • [8] A phase 2, open-label, adaptive, dose-ranging study with long-term extension to evaluate the safety, tolerability, efficacy, and pharmacokinetics of intra-articular AMB-05X injections in patients with tenosynovial giant cell tumor
    Gelderblom, Hans
    Bhadri, Vivek
    Randall, R. Lor
    Scharschmidt, Thomas
    Tap, William D.
    Alani, Laman
    Johnson, Kirk
    Leyva, Stephanie
    Nguyen, Dorothy D.
    Nguyen, Tiffany
    van de Sande, Michiel A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] A phase 1/2a open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of AFM24 in patients with advanced solid cancers: Study design and rationale
    Santa Gadea, Omar Saavedra
    Garralda, Elena
    Suzanne Lopez, Juanita
    Awad, Mark M.
    Stephen Thomas, Jacob
    Diane Tiu, Crescens
    Morales-Espinosa, Daniela
    Raab, Christa
    Rehbein, Bettina
    Hintzen, Gabriele
    Pietzko, Kerstin
    Ravenstijn, Paulien
    Emig, Michael
    El-Khoueiry, Anthony B.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Updated results from a dose-escalation study in adults with severe or moderate-severe hemophilia B treated with AMT-060 (AAV5-hFIX) gene therapy: up to 1.5 years follow-up
    Schwaeble, J.
    Miesbach, W.
    Meijer, K.
    Coppens, M.
    Kampmann, P.
    Klamroth, R.
    Schutgens, R.
    Castaman, G.
    Seifried, E.
    Boenig, H.
    Meyer, C.
    Cattaneo, F.
    Leebeek, F.
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2017, 44 : 10 - 10
12345